SCHEMBL21591792

SCHEMBL21591792

Cc1ccc(CNc2cc(-c3c[nH]c4nccc(Oc5ccc6c(c5)CNCC6)c34)ccn2)nc1

nearest known ligand 0.37

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.37
AURKB Q96GD4 2/20 0.37
INCENP Q9NQS7 2/20 0.37
ROCK1 Q13464 12/20 0.35
CDC42BPB Q9Y5S2 12/20 0.35
ROCK2 O75116 10/20 0.35
CDC42BPA Q5VT25 4/20 0.34
MAP4K1 Q92918 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29836477 1.00 SYK (0.37) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL23762196 0.86 CDC7 (0.38) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL21593089 0.85 BUB1 (0.37) ROCK1CDC42BPBROCK2CDC42BPACYP2C19
SCHEMBL29836498 0.85 BUB1 (0.37) ROCK1CDC42BPBROCK2CDC42BPACYP2C19
SCHEMBL21591768 0.84 ROCK2 (0.39) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL29836446 0.84 ROCK2 (0.39) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL21591767 0.84 ROCK1 (0.41) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL29836303 0.84 ROCK1 (0.41) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL21593205 0.84 ROCK1 (0.34) SYKAURKBINCENPROCK1CDC42BPB
SCHEMBL29836549 0.84 ROCK1 (0.34) SYKAURKBINCENPROCK1CDC42BPB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP claimed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US claimed
EP-3807273-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2021-04-21 EP claimed
WO-2019238628-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2019-12-19 WO claimed
EP-3807273-B1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARM SPA (IT) 2022-08-03 EP disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-08-19 US disclosed
WO-2019238628-A1 AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253568-A1 AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS ROCK1, ROCK2, RHOA SYK 1140/4885AURKB 615/4885INCENP 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.